Staking INJ ETF Clears Major Hurdle with Third S-1 Amendment Filing
Investment manager Canary Capital has filed a third amended S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) for a novel exchange-traded fund centered on Injective's INJ token. The move, announced by Injective's official channels, signals advanced progress in the product's path to market.
A Hybrid Model: Spot Ownership Meets Staking Rewards
The proposed ETF breaks from conventional crypto fund structures. Its key innovation lies in a commitment to stake a significant portion of its assets. According to the filing, the fund intends to stake at least 90% of its U.S.-based institutional holdings of spot INJ tokens directly on the Injective network.
This design offers investors a dual benefit: exposure to the potential price appreciation of INJ and a pass-through of the rewards generated from network validation. It effectively creates a bridge for institutional capital to access crypto-native yield mechanisms within a regulated wrapper, addressing common operational and compliance barriers.
Implications and the Road Ahead
Market participants interpret this third amendment as a strong indicator that the SEC review process is entering its final stages. Typically, a third filing suggests regulator questions are being resolved, bringing a potential launch date closer into view.
Successful approval would set a notable precedent, introducing one of the first mainstream investment vehicles to explicitly integrate on-chain staking rewards. This could open the door for similar products tied to other proof-of-stake cryptocurrencies, further blurring the lines between decentralized finance and traditional investment portfolios.
All eyes are now on the SEC's response. The final structure and listing timeline depend on regulatory clearance. This filing undeniably represents a significant step forward in the evolution of crypto-based financial instruments.